IPSEN (OTCMKTS:IPSEY) Short Interest Update

IPSEN (OTCMKTS:IPSEY - Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 600 shares, a drop of 45.5% from the May 15th total of 1,100 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.0% of the company's stock are short sold.

IPSEN Stock Performance

Shares of OTCMKTS IPSEY traded down $0.77 during trading on Wednesday, hitting $29.34. The stock had a trading volume of 726 shares, compared to its average volume of 4,611. IPSEN has a 12 month low of $25.11 and a 12 month high of $32.25. The firm has a fifty day moving average of $28.77 and a two-hundred day moving average of $29.26.

IPSEN Increases Dividend

The firm also recently declared a dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be paid a dividend of $0.2896 per share. The ex-dividend date of this dividend is Monday, June 9th. This is an increase from IPSEN's previous dividend of $0.23. This represents a dividend yield of 0.97%.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of IPSEN in a research note on Wednesday, April 2nd.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.